Intermittent androgen-deprivation therapy in prostate cancer: A critical review focused on phase 3 trials

European Urology

Volumn 64, Issue 5, 2013, Pages 722-730

  Sciarra, Alessandro ^a   Abrahamsson, Per Anders ^b   Brausi, Maurizio ^c   Galsky, Matthew ^d   Mottet, Nicolas ^e   Sartor, Oliver ^f   Tammela, Teuvo L J ^g   Calais Da Silva, Fernando ^h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b LUND UNIVERSITY   (Sweden)

^c Nuovo Ospedale S Agostino   (Italy)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Clinique Mutualiste de la Loire   (France)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g TAMPERE UNIVERSITY HOSPITAL   (Finland)

^h Universidade de Lisboa   (Portugal)

Author keywords

Androgen deprivation; Intermittent therapy; Prostate neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTINUOUS ANDROGEN DEPRIVATION THERAPY; FOLLOW UP; HUMAN; INTERMITTENT ANDROGEN DEPRIVATION THERAPY; METASTASIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANDROGEN DEPRIVATION; INTERMITTENT THERAPY; PROSTATE NEOPLASM;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885426028     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.04.020     Document Type: Review

References (38)

1. P.A. Abrahamsson Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49 59
2. L.H. Klotz, H.W. Herr, M.J. Morse, and W.F. Whitmore Jr. Intermittent endocrine therapy for advanced prostate cancer Cancer 58 1986 2546 2550
3. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/ 08%20Prostate%20Cancer-LR%20March%2013th%202012.pdf.
4. N. Bruchovsky, P.S. Rennie, A.J. Coldman, S.L. Goldenberg, M. To, and D. Lawson Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 50 1990 2275 2282
5. N. Sato, M. Gleave, and N. Bruchovsky Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model J Steroid Biochem Mol Biol 58 1996 139 146
6. K. Akakura, N. Bruchovsky, S.I. Goldenberg, P.S. Rennie, A.R. Bukley, and L.D. Sullivan Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate specific antigen Cancer 71 1993 2782 2790
7. A. Sciarra, S. Monti, and V. Gentile Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma Prostate 55 2003 168 172
8. D. Prapotnich, X. Cathelineau, and F. Rozet A 16 year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results World J Urol 27 2009 627 635
9. J. De Leval, P. Boca, and E. Yousef Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naïve prostate cancer: results of a prospective randomize multicentre trial Clin Prostate Cancer 1 2002 163 171
10. F. Calais da Silva, A. Bono, and P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group Eur Urol 52 2009 1269 1277
11. A.J. Salonen, K. Taari, M. Ala-Opas, J. Viitanen, S. Lundstedt, T.L. Tammela FinnProstate Group The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer J Urol 187 2012 2074 2081
12. M. Hussain, C.M. Tangen, and D.L. Berry Intermittent versus continuous androgen deprivation in prostate cancer NEJM 368 2013 1314 1325
13. J.M. Crook, C. O'Calleghan, and G. Dincan Intermittent androgen suppression for rising PSA level after radiotherapy [published correction appears in N Engl J Med 2012;367:2262] N Engl J Med 367 2012 895 903
14. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous versus intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol. In press.
15. N. Mottet, J. Van Damme, S. Loulidi, C. Russel, A. Leitenberger, J.M. Wolff TAP22 Investigators Group Intermittent hormone therapy in the treatment of metastatic prostate cancer: a randomized trial BJU Int 110 2012 1262 1269
16. U. Tunn, O. Eckhart, E. Kienle, and H. Hillger Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy - first results of a randomised prospective phase-III clinical trial (AUO study AP06/95) Eur Urol Suppl 2 1 2003 24
17. N. Mottet, J. Bellmont, and M. Bolla EAU guidelines on prostate cancer Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
18. N. Shore, and D. Crawford Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 12 2010 1 11
19. A. Zlotta, and F.M.J. Debruyne Expert opinion on optimal testosterone control in prostate cancer Eur Urol Suppl 4 8 2005 37 41
20. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrated levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
21. Y. Wang, S. Gupta, and V. Hua Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model Prostate 70 2010 147 154
22. F. Di Silverio, A. Sciarra, and V. Gentile Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy Urology 71 2008 947 951
23. W.D. Figg, M.H. Hussain, and J.L. Gulley A double blind randomized crossover study of oral thalidomide versus placebo in patients with stage D0 androgen dependent prostate cancer following limited androgen ablation J Urol 181 2009 1104 1113
24. Oxford Centre for Evidence-based Medicine levels of evidence (March 2009). Centre for Evidence-based Medicine Web site. http://www.cebm.net/index. aspx?o=1025.
25. J.L. Shaw, P. Wilson, and J. Cuzick International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta analysis of 1446 patients BJU Int 99 2007 1056 1065
26. P.D. Conti, A.N. Atallah, H. Arruda, B.G. Soares, R.P. El Dib, and T.J. Wilt Intermittent versus continuous androgen suppression for prostate cancer Cochrane Database Syst Rev 2007 CD005009
27. K. Miller, U. Steiner, and A. Lingnau Randomized prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5015] J Clin Oncol 25 Suppl 2007
28. M. Hussain, C.M. Tangen, and C.S. Higano Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients: results of S9346 (INT-0162), an international phase III trial [abstract 4] J Clin Oncol 30 Suppl 2012
29. J.L. Mohler, A.J. Armstrong, and R.R. Bahnson Prostate cancer, version 3.2012: featured updates to the NCCN guidelines J Natl Compr Canc Netw 10 2012 1081 1087
30. D. Gruca, P. Bacher, and U. Tunn Safety and tolerability of intermittent androgen deprivation therapy: a literature review Int J Urol 19 2012 614 625
31. A.J. Salonen, K. Taari, M. Ala-Opas, J. Viitanen, S. Lundstedt, T. Tammela FinnProstate Group Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects Eur Urol 63 2013 111 120
32. D. Prapotnich, K. Fizazi, B. Escudier, A. Mombet, N. Cathala, and G. Vallancien A 10-year clinical experience with intermittent hormonal therapy for prostate cancer Eur Urol 43 2003 233 240 discussion 239-40
33. M. Gleave, I. Klotz, and S.S. Taneja The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer Urol Oncol 27 2009 81 86
34. D. Keizman, P. Huang, and E.S. Anotonarakis The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation Prostate 71 2011 1608 1615
35. Sciarra A, Cattarino S, Gentilucci A, et al. Predictors for response to intermittent androgen deprivation in prostate cancer patients with biochemical progression after surgery. Urol Oncol. In press.
36. Y.J. Yu, R. Gulati, and D. Telesca Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation J Clin Oncol 28 2010 2668 2673
37. Prostate cancer. Guideline for the management of clinically localized prostate cancer: 2007 update. American Urological Association Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/proscan07/content.pdf.
38. D.A. Loblaw, K.S. Virgo, and R. Nam American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605